MassBio's Strategic Plan

Posts tagged ‘Twitter Chat’

Defining Value

MassBio continued its #Impact2020 Twitter Chat Series with a discussion on defining value. Impact 2020 examines the balance between value-based, evidence-based medicine in the era of healthcare reform and the uncertainty it creates for investors and entrepreneurs who seek reward for innovation and risk-taking. Value creation is, and will continue to be critical to success in the life sciences industry.

In the chat, we discussed how key stakeholders define value and how companies can work to demonstrate value in today’s healthcare system.

Click here to check out the conversation!

defining value screenshot

Advertisements

Rare Disease Research

MassBio continued its #Impact2020 Twitter Chat Series with a discussion of rare disease research today and tomorrow, in Massachusetts and beyond.

There are approximately 30 million people living with a rare disease in the USA, between 27 and 36 million in the EU, and collectively around the globe, the rare disease community is estimated to include 350 million people. There are more than 7,000 rare diseases, many of them with no treatment or cure.

Many rare disease therapies are under development in Massachusetts and these leading researchers are pushing for accelerated approval pathways.

In this Twitter chat, we discussed the current state of rare disease research, the clinical and regulatory challenges for rare disease research, and how patients and patient advocates are making a difference.

Click here to read the conversation!

rare twitter chat

Early-Stage Funding, New Models for Success

Building buzz for Impact 2020: The MassBio Strategic Report, we continued our #Impact2020 Twitter Chat Series last night. In the chat we focused on the evolution & future of early-stage funding in life sciences with moderator John Hallinan, Chief Business Officer at MassBio, and guest moderator David Berry, Partner at Flagship Ventures.

From pharma-based venture funds to advocacy group-directed research to crowd-funding, we’re in the midst of a sea change in how emerging biotechs find funding and address capital challenges. The IPO window reopened in 2013 but how long can we expect it to stay open? With a significant decline in seed stage funding, are Massachusetts’ good ideas being funded? How do we continue to support fledgling companies that need startup money for early research or proof-of-concept?

Click here to check out the conversation!

Storify Screenshot!

Crossroads of Biotech & IT

Building buzz for Impact 2020: MassBio’s Strategic Report, we hosted our second Twitter Chat last night, this time focused on the intersection of biotech, tech, and devices & diagnostics in Massachusetts. Thank you to all who joined us and a special thanks to our guest moderator, Tom Hopcroft, President and CEO of Massachusetts Technology Leadership Council.

In this chat we discussed:

  • Should life sciences and technology seek to collaborate more than they do now?
  • Is the combination of devices, IT, diagnostics, and biotech potent enough to catalyze unique collaborations and spawn new industry models?
  • What can Big Data do for life sciences and vice versa?
  • Who will spearhead these partnerships and why doesn’t more seem to be happening?

Check out the conversation!

Impact 2020 Screenshot #2

It’s Who You Know

Building buzz for Impact 2020: The MassBio Strategic Report, we hosted our first ever Twitter Chat last night – thank you to all who joined us!  This chat was focused on one of the report’s findings that Massachusetts is such a tight-knit biotech community that sometimes “It’s Who You Know” that makes a difference.

Those new to the local scene are quick to note the powerful relationships they encounter among us locals. Tapping into that community can be daunting, and led one recent stakeholder to call the Massachusetts biotech community “The Club” when being interviewed for the Impact 2020 report.

On the other hand, our tight-knit community means that entrepreneurs have near-instant access to a wide variety resources, and there’s a good chance we’re all six degrees of professional separation from Bob Langer or Henri Termeer.

What does our close community mean to you, and how can we make sure our network works to build the Massachusetts cluster?

Click here to check out the conversation!

Impact 2020 Screenshot #1